To evaluate the potential contribution of amyloid burden, as indexed by 11C-Pittsburgh compound B (PiB) retention, to the progression of cognitive impairments in patients with Parkinson's disease(PD).
Study design: Multi-center, Five-arm Subjects: Patients with PD without dementia; Patients with PD with mild cognitive impairment (MCI); Patients with PD with dementia; Patients with a dementia with Lewy bodies(DLB); Healthy person Sample size: 200, including a PD without dementia group of 75 patients, a PD with MCI group of 30 patients, a PD with dementia group of 20 patients, a DLB group of 25 patients and a normal control group of 50 subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
200
11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
Peking Tian Tan Hospital, Capital Medical University
Beijing, China
RECRUITINGTianjin Huanhu Hospital
Tianjin, China
RECRUITINGTianjin Medical University General Hospital
Tianjin, China
RECRUITINGAmyloid burden range in all subjects
Outcome Measures: All patients underwent a 90-min dynamic 11C-PIB PET scan. 11C-PiB distribution volume ratio (DVR) will be estimated by using the PMOD software.
Time frame: 1 week
The cognitive scores in all patients
Functional status is assessed by the Mini-Mental State Examination (MMSE). Parkinson disease with mild cognitive impairment:MMSE score 24-28; Parkinson disease with dementia: MMSE score ≤24; Parkinson disease with normal cognition: MMSE score \>28.
Time frame: 0, 6month, 1year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.